Tuberculosis (TB) is a bacterial infection spread through inhaling tiny droplets from the coughs or sneezes of an infected person. Tuberculosis (TB) is caused by a bacterium called Mycobacterium tuberculosis. The bacteria usually attack the lungs, but TB bacteria can attack any part of the body such as the kidney, spine, and brain. Not everyone infected with TB bacteria becomes sick. As a result, two TB-related conditions exist: latent TB infection (LTBI) and TB disease.
“Tuberculosis Pipeline Insight, 2022” report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Tuberculosis Market.
The Tuberculosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Request for sample and discover more about the Tuberculosis report offerings @ Tuberculosis Pipeline Insight
Tuberculosis Stages
Tuberculosis (TB) is a chronic, progressive mycobacterial infection, often with a period of latency following initial infection. Tuberculosis may occur in 3 stages:
• Primary infection- M. Tuberculosis bacilli initially cause a primary infection, which uncommonly causes acute illness.
• Latent infection- Most (about 95%) primary infections are asymptomatic and followed by a latent (dormant) phase.
• Active infection- A variable percentage of latent infections subsequently reactivate with symptoms and signs of disease.
Tuberculosis Treatment
Tuberculosis is a treatable and curable disease. Active, drug-susceptible TB disease is treated with a standard 6-month course of 4 antimicrobial drugs that are provided with information and support to the patient by a health worker or trained volunteer. The most common medications used to treat tuberculosis include: Rifampin, Isoniazid, Pyrazinamide and Ethambutol.
Find a snapshot of the Tuberculosis Treatment landscape @ Tuberculosis Therapies and drugs
Tuberculosis Therapeutics Assessment
- Therapeutic Assessment By Tuberculosis Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment By Tuberculosis Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Therapeutics Assessment By Tuberculosis Route of Administration: Oral, Parenteral, Subcutaneous, Topical, Intravenous
- Therapeutics Assessment By Tuberculosis Molecule Type: Gene therapy, Small molecule, Polymers, Peptides, Monoclonal antibodies
- Therapeutics Assessment By Tuberculosis Mechanism of Action: Bacterial growth inhibitors, Electron transport complex III inhibitors, Leukotriene inhibitors, Immunostimulants, Adenosine triphosphatase inhibitors, DprE1 protein inhibitors, Interferon type I stimulants; T lymphocyte stimulants.
Tuberculosis Causes
Tuberculosis is caused by bacteria that spread from person to person through microscopic droplets released into the air. This can happen when someone with the untreated, active form of Tuberculosis coughs, speaks, sneezes, spits, laughs or sings. Although Tuberculosis is contagious, it’s not easy to catch. Most people with active TB who’ve had appropriate drug treatment for at least two weeks are no longer contagious.
Tuberculosis Emerging Drugs
Telacebec (Q203): Qurient Co
Telacebec (Q203) is one of the first candidates getting close to forming new universal regimen. Telacebec (Q203) is an orally active small molecule drug candidate that blocks Mycobacterium tuberculosis growth by inhibiting cytochrome bc1 complex, leading to the depletion of adenosine triphosphate (ATP) synthesis of M. tuberculosis. Telacebec (Q203) shows good synergy with bedaquiline in murine chronic infection model, indicating promising potential for new drug regimen. The drug is currently in phase 2 stage of development.
VPM1002: Serum Institute of India
VPM1002 facilitates mycobacterial antigens being released into the cytosol while also triggering autophagy, inflammasome activation, and apoptosis, because of antigens and bacterial DNA being released into the cytosol of the host cell due to Listeriolysin O expression in this vaccine. Mycobacterial antigen accessing the cytosol also improves antigen presentation. The ability for mycobacterial antigens to reach the cytosol is due to this vaccine being engineered to secrete Hly which perforates phagosomal membranes. Currently, it is in phase III stage of development for the treatment of Tuberculosis.
Tuberculosis Phases
DelveInsight’s Tuberculosis report covers around 35+ products under different phases of clinical development like
- Late stage Tuberculosis products (Phase III)
- Mid-stage Tuberculosis products (Phase II)
- Early-stage product (Phase I)
- Tuberculosis Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Tuberculosis Route of Administration
Learn more about Tuberculosis Drugs Pipeline @ Tuberculosis clinical trials
Table of Content
- Introduction
- Executive Summary
- Tuberculosis: Overview
- Tuberculosis Pipeline Therapeutics
- Tuberculosis Therapeutic Assessment
- Late Stage Products (Phase III)
- Telacebec (Q203): Qurient Co
- Mid Stage Products (Phase II)
- WX-081: Shanghai Jiatan Pharmatech
- Early Stage Products (Phase I/II)
- OPC-167832: Otsuka Pharmaceutical
- Inactive Tuberculosis Products
- Tuberculosis Key Companies
- Tuberculosis Key Products
- Tuberculosis Unmet Needs
- Tuberculosis Market Drivers and Barriers
- Tuberculosis Future Perspectives and Conclusion
- Tuberculosis Analyst Views
- Tuberculosis Key Companies
- Appendix
Get in touch with our Business Consultant to get detailed insights into – Tuberculosis Pipeline Assessment
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/tuberculosis-pipeline-insight